引用次数
引用: 9,323
H-指数: 40
I10-指数 : 63
出版物: 146
Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils.
S Martinelli , G Kostylina , V Niggli , C Baumann
Oncogene 25 ( 52) 6915 -6923
14
2006
Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis
J H Schatz , S M Horwitz , J Teruya-Feldstein , M A Lunning
Leukemia 29 ( 1) 237 -241
44
2015
MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia
E Mets , J Van der Meulen , G Van Peer , M Boice
Leukemia 29 ( 4) 798 -806
64
2015
Progress against follicular lymphoma.
Jonathan H. Schatz , Elisa Oricchio , Soham D. Puvvada , H. Guido Wendel
Current Opinion in Hematology 20 ( 4) 320 -326
8
2013
Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma.
Matthew G. Fury , Marija Drobnjak , Camelia S. Sima , Marina Asher
Head and Neck-journal for The Sciences and Specialties of The Head and Neck 33 ( 9) 1340 -1345
13
2011
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo
M. G. Kris , H. I. Scher , V. A. Miller , F. M. Sirotnak
Clinical Cancer Research 6 ( 9) 3705 -3712
38
2000
Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene.
X. Chen , N. Mitsutake , K. LaPerle , N. Akeno
Proceedings of the National Academy of Sciences of the United States of America 106 ( 19) 7979 -7984
93
2009
Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia
V. R. Sanghvi , K. J. Mavrakis , J. Van der Meulen , M. Boice
Science Signaling 7 ( 352)
28
2014
MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia
E. Mets , G. Van Peer , J. Van der Meulen , M. Boice
Haematologica 99 ( 8) 1326 -1333
41
2014
Dissecting eIF4E action in tumorigenesis
H.-G. Wendel , R. L.A. Silva , A. Malina , J. R. Mills
Genes & Development 21 ( 24) 3232 -3237
369
2007
Tumorigenic activity and therapeutic inhibition of Rheb GTPase
K. J. Mavrakis , H. Zhu , R. L.A. Silva , J. R. Mills
Genes & Development 22 ( 16) 2178 -2188
93
2008
mTORC1 promotes survival through translational control of Mcl-1
J. R. Mills , Y. Hippo , F. Robert , S. M. H. Chen
Proceedings of the National Academy of Sciences of the United States of America 105 ( 31) 10853 -10858
198
2008
Mouse models of cancer as biological filters for complex genomic data.
E. Oricchio , A. L. Wolfe , J. H. Schatz , K. J. Mavrakis
Disease Models & Mechanisms 3 701 -704
6
2010
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
H.-G. Wendel , E. de Stanchina , E. Cepero , S. Ray
Proceedings of the National Academy of Sciences of the United States of America 103 ( 19) 7444 -7449
111
2006
EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC
Fagin JA9. Krishnamoorthy GP1 , Davidson NR2 , Leach SD1 , Zhao Z3
Cancer discovery
70
2018
Tnfrsf14/ hvem proteins and methods of use thereof
Darin Salloum , Hans Guido Wendel , Michael Henry Boice
1
2016
Abstract A47: The immunoproteosome mediates resistance to natural killer cell killing
Hans Guido Wendel , Joyce Pasion
Cancer immunology research 8
2020
NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy
Marjan Berishaj , Elisa de Stanchina , Viraj R. Sanghvi , Viraj R. Sanghvi
Cancers 13 ( 4) 639
2021
Methods for treatment of lymphomas with mutations in cell cycle genes
Hans Guido Wendel , Elisa Oricchio
34
2016
Tnfrsf14/hvem proteins and methods of use thereof
Michael Henry Boice , Hans Guido Wendel , Darin Salloum
2022